Optimal Management of Women With Wrist Fractures

This study has been completed.
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by:
Queen's University
ClinicalTrials.gov Identifier:
NCT00226031
First received: September 22, 2005
Last updated: June 23, 2008
Last verified: June 2008

September 22, 2005
June 23, 2008
September 2003
August 2006   (final data collection date for primary outcome measure)
Proportion of women who are prescribed anti-osteoporosis therapy within 6 months of sustaining a forearm fracture. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Proportion of women who are prescribed anti-osteoporosis therapy within 6 months of sustaining a forearm fracture.
Complete list of historical versions of study NCT00226031 on ClinicalTrials.gov Archive Site
  • Proportion of women in whom a bone density scan is ordered and the proportion of women who receive counseling advice about osteoporosis from their family physicians. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Women's knowledge about osteoporosis and fractures (Osteoporosis Knowledge Questionnaire). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Proportion of women in whom a bone density scan is ordered and the the proportion of women who receive counselling advice about osteoporosis from their family physicians.
  • Women's knowledge about osteoporosis and fractures (Osteoporosis Knowledge Questionnaire).
Not Provided
Not Provided
 
Optimal Management of Women With Wrist Fractures
Optimal Management of Older Women With Distal Forearm Fractures

To evaluate the effectiveness of a multifaceted intervention (reminder and educational material) in improving the evaluation of osteoporosis follow-up care of post-menopausal women with wrist fractures by their primary care physicians. The intervention is directed at improving the gap in continuity of care between emergency/fracture clinics and family physicians, and reducing knowledge gaps.

Numerous studies have demonstrated that women with wrist fractures have lower bone mineral density. Despite new guidelines for the care of such women, research has shown that they are not generally evaluated for osteoporosis. This care gap exists although it is known that wrist fractures are an important marker for subsequent fractures, such as a hip fracture, which represents a significant socio-economic burden to society.

Comparison: Cluster randomized trial of women and their physicians, both of whom receive educational material and reminder on post fracture osteoporosis evaluation. Comparison is to women and their physicians who receive standard post fracture information. Family practices are randomized to intervention or non-intervention group.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Osteoporosis
  • Osteopenia
Procedure: Educational Material and Reminder
Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
  • No Intervention: 1
    Usual care.
    Intervention: Procedure: Educational Material and Reminder
  • Experimental: 2
    Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
    Intervention: Procedure: Educational Material and Reminder
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
270
August 2007
August 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Postmenopausal women with low trauma distal radius fracture (confirmed by x-ray).
  2. Can be taking Didrocal (etidronate), Miacalcin (calcitonin),or hormone replacement therapy .

Exclusion Criteria:

  1. Women with fractures of the elbow, mid radius, scaphoid, or injury to wrists (without actual fracture).
  2. Significant cognitive impairment (which would preclude them from filling out simple questionnaires).
  3. Women already taking osteoporosis therapy, ie. either Fosamax (alendronate), Actonel (risedronate), or the selective estrogen receptor modulator, Evista (raloxifene).
Female
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00226031
KTS-62358
No
Dr. Ann Cranney, University of Ottawa
Queen's University
Canadian Institutes of Health Research (CIHR)
Principal Investigator: Ann B Cranney, MD Queen's University
Queen's University
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP